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Abstract: Fluorescent protein biosensors are powerful cellular systems biology tools for 
dissecting the complexity of cellular processes with high spatial and temporal resolution. 
As regulated nucleo-cytoplasmic transport is crucial for the modulation of numerous 
(patho)physiological cellular responses, a detailed understanding of its molecular 
mechanism would open up novel options for a rational manipulation of the cell. In contrast 
to genetic approaches, we here established and employed high-content cellular 
translocation biosensors applicable for dissecting nuclear export by chemicogenomics. 
A431 cell lines, stably expressing a translocation biosensor composed of glutathione S-
transferase, GFP and a rational combination of nuclear import and export signals, were 
engineered by antibiotic selection and flow cytometry sorting. Using an optimized nuclear 
translocation algorithm, the translocation response could be robustly quantified on the 
Cellomics Arrayscan
® VTI platform. Subsequent to assay optimization, the assay was 
developed into a higher density 384-well format high-content assay and employed for the 
screening of the 17K ChemBioNet compound collection. This library was selected on the 
basis of a genetic algorithm used to identify maximum common chemical substructures in 
a database of annotated bioactive molecules and hence, is well-placed in the chemical 
space covered by bioactive compounds. Automated multiparameter data analysis combined 
with visual inspection allowed us to identify and to rationally discriminate true export 
OPEN ACCESSSensors 2009, 9                  
 
 
5424
inhibitors from false positives, which included fluorescent compounds or cytotoxic 
substances that dramatically affected the cellular morphology. A total of 120 potential hit 
compounds were selected for Cellomics Arrayscan
® VTI based rescreening. The export 
inhibitory activity of 20 compounds effective at concentrations < 25 μM were confirmed 
by fluorescence microscopy in several cell lines. Interestingly, kinetic analysis allowed the 
identification of inhibitors capable to interfere with the export receptor CRM1-mediated 
nuclear export not only in an irreversible, but also in a reversible fashion. In sum, 
exploitation of biosensor based screening allows the identification of chemicogenomic 
tools applicable for dissecting nucleo-cytoplasmic transport in living cells. 
Keywords:  chemical biology; cancer; Exportin 1/CRM1; HIV-1 Rev; import; LMB; 
nucleocytoplasmic transport; nucleoporin 
 
1. Introduction 
 
1.1. Cellular Biosensors 
 
According to the International Union of Pure and Applied Chemistry (IUPAC; 
http://www.iupac.org), a biosensor is a device that uses biochemical reactions mediated by isolated 
enzymes, organelles or whole cells to detect the effects of chemical compounds by electrical, thermal 
or optical signals. However, for many biological questions sensors that detect only one parameter in 
vitro appear to be inefficient for dissecting the regulation of complex biological systems. The 
complexity of living organisms causes the need for a new class of sensors capable of integrating and 
interpreting multiple parameters into simple read outs. Such a need is also reflected by the recent shift 
in focus from the single gene, single target, single pathway and single drug paradigm to a more 
“systems biology” perspective, not only in basic science but also in drug development (details in [1,2]).  
As cellular biosensors have the advantage of acting in a physiological and/or pathophysiological 
environment (e.g., in cancer cells), these are beginning to be widely used in cell and molecular biology 
to define the dynamics of cellular regulation in time and space, especially when combined with 
automated multi-parameter imaging technologies ([1,3,4] and references within). Also, the dramatic 
increase in the use of cell-based assays during all major steps of drug discovery and development has 
increased the demand for novel cellular biosensors. Such biosensors are expected to allow the 
detection of a wide variety of signaling molecules in real-time and hence, are bearing the potential for 
novel assay applications. Intensifying the use of kinetic, compared with snapshot, cell screening assays 
is expected to reveal subtle, but discrete effects of compounds, aiding the interpretation of their mode 
of action and leading to an improved understanding of key regulatory cellular pathways. 
During the last years cell based high content screening (HCS) has evolved so that the throughput is 
high enough even for current primary high throughput screening (HTS) applications, measuring the 
temporal and spatial responses of cells to drugs and biological treatments (see [5]). The information 
gained from these high-content assays can be used to build a knowledge base from which better Sensors 2009, 9                  
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decisions about potential new lead compounds can be made early in the drug discovery pipeline based 
on “functional cellular responses” [1].  
The ability to automate the capture and analysis of fluorescent images of thousands of cells in the 
wells of microtiter plates has made fluorescence microscopy one of the premier tools of cell biology, 
compatible with drug discovery [6]. Individual and population average measurements can be made 
rapidly on adherent cells with whole plate readers enabling the rapid measurement of a variety of 
treatments as well as fast kinetic measurements of treatment. Whereas both luminescent and 
fluorescent reagents have been successfully applied to a variety of functional measurements, 
fluorescence-based reagents have dominated so far due to the specificity, sensitivity, and temporal 
detection possible in sub-second time domains. However, the combined use of luminescent and 
fluorescent sensors will certainly be optimal to accelerate new discoveries and enable improved high 
content screening in the future (see [5]). 
Often, redistribution approaches, a cell-based assay technology that uses protein translocation as the 
primary readout have been used to study the activity of cellular signaling pathways and other 
intracellular events. Protein targets are labeled with autofluorescent proteins (e.g., the green 
fluorescent protein – GFP), and stably expressing cell lines are generated. The assays are read using a 
high-throughput, optical microscope-based instrument, several of which have become available 
commercially. Such assays can be formatted as agonist assays, in which compounds are tested for their 
ability to promote protein translocation, or as antagonist assays, in which compounds are tested for 
their ability to inhibit protein translocation caused by a known agonist. Protein translocation assays 
have the potential for high-content, high-throughput assays for the profiling of lead series, primary 
screening of compound libraries, or even as readouts for gene-silencing studies [7,8]. However, any 
realistic applications of high-content and high-throughput cell based assays critically depend on robust 
and reliable biological readout systems with a high signal to noise ratio. In this context, the spatial and 
functional division into the nucleus and the cytoplasm marks not only two dynamic intracellular 
compartments vital for the cell but that can also be easily distinguished by microscopy. 
 
1.2. Nucleo-Cytoplasmic Transport 
 
The eukaryotic cell is divided into distinct reaction compartments, which enables the fine-tuning of 
biochemical processes being fundamental for cellular specialization and thus, for the development of 
higher eukaryotes. However, the full exploitation of this regulatory potential necessitates the 
controlled intracellular localization and transport of proteins and macromolecules (see [9]). In 
particular, the integration of signals from the (extra)cellular microenvironment into adaptive cellular 
responses, including the modulation of genetic programs, critically depends on regulated nucleo-
cytoplasmic transport (Figure 1a) [10,11]. The nucleus is separated from the cytoplasm by the nuclear 
envelope bilayer, which can only be passaged through the nuclear pore complexes (NPCs), large 
macromolecular machines of ~125 MDa (details in [12-14]). The NPC can be divided into cytoplasmic 
fibrils, a central core and the nuclear basket. Major structural and functional constituents of the NPC 
are the so called nucleoporins, a group of proteins with ~30 known members (references in [12,13]). 
 Sensors 2009, 9                  
 
 
5426
Figure 1. (a) Schematic illustration of the regulation of nucleo-cytoplasmic transport. As 
an example for nuclear export, the CRM1-dependent pathway is depicted. (b) Heat-repeat 
map of CRM1, which is predicted to contain 19 repeats separated by a loop within repeat 8. 
(c) Kinetic classification of NES sequences established by microinjection experiments of 
recombinant GST-NES-GFP substrates into the nucleus. Amino acids essential for function 
are highlighted in grey, putative consensus sequence for leucine-rich NES is shown below. 
 
(a) NLS-bearing cargoes are imported via binding to importins. In the nucleus, the importin-cargo complex 
dissociates upon RanGTP binding. CAS exports the respective importin back into the cytoplasm. RanGAP 
hydrolyses RanGTP to RanGDP resulting in release of the importin from CAS. Leucine-rich NES-bearing 
cargoes bind to CRM1 in the presence of RanGTP, and the complex translocates into the cytoplasm, where the 
cargo is released following hydrolysis of RanGTP to RanGDP. RanGDP is reimported by NTF2 and reconverted 
into RanGTP by RanGEF. Leptomycin B (LMB) inactivates CRM1 by covalent binding to Cys528, thereby 
irreversibly inhibiting NES-mediated nuclear export. For the selective export of cargoes, NES-specific 
cofactors (X) have been suggested. RanGEF - Ran guanine nucleotide exchange factor, RanGAP - Ran 
GTPase activating protein 1, NTF2 - Nuclear Transport Factor 2, CAS - cellular apoptosis susceptibility, X – 
putative NES-specific cofactor. (b) Heat repeat 10 contains the cysteine residue 528, which is covalently 
modified by LMB. The C-terminal region (CTR) comprises heat repeats 14 to 19, colored from yellow to 
black. The CTRs of two proteolytic fragments of CRM1 (residues 707-1027, PDB 1W9C) are displayed as a 
dimeric solid ribbon representation of the backbone superposition (heat repeats of one fragment colored as 
above). Sensors 2009, 9                  
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The NPC is a selective barrier for molecules larger than 40-60 kDa and allows transport of cargoes 
with diameters up to 40 nm [14,15]. One NPC can perform up to 1,000 translocation events per second, 
which can also occur against a concentration gradient, and is mediated by soluble transport factors that 
in turn shuttle between the nucleus and the cytoplasm ([14] and references within). Importantly, even 
molecules that are theoretically small enough for passive diffusion are actively and selectively 
transported (see [3,14]). Regulated transport of most proteins and several RNA species [10] is 
mediated by karyopherins, belonging to the superfamily of importin β-related proteins [16]. 
Karyopherins are also named importins and exportins according to their catalyzed mode of transport. It 
is striking that the 20 karyopherin members are capable of mediating the controlled transport of the 
huge variety of cargoes, which differ dramatically with respect to their biochemical and -physical 
properties. Hence, the exact mechanism ensuring the flexibility and correct regulation of nuclear 
transport are still not resolved, but appear to rely on a complex network of dynamic protein 
interactions involved in the formation of general and selective transport complexes as well as in the 
passage through the NPCs itself (see [11,17]. 
In contrast to receptors, which interact with only one or a few structurally related cargoes, import 
receptors such as importin α/β or the export receptor CRM1 (chromosome region maintenance)/ 
exportin1 (Figure 1b), transport numerous proteins and/or ribonucleoprotein complexes by recognizing 
specific signal sequences present in the cargo and/or associated adapter proteins (see  [14,18]). 
Importins bind to short stretches of basic amino acids, termed nuclear localization signals (NLS). The 
best characterized nuclear export signals (NESs) are hydrophobic and consist of a short leucine-rich 
stretch of amino acids (Figure 1a/c) [3,14,18]. Although also CRM1-independent pathways are crucial 
for cellular homeostasis, CRM1-independent NES are less well characterized (for details 
see [3,14,17,18] and references within). Recognition of the NES by the CRM1 receptor is speciﬁcally 
inhibited by LMB, which binds covalently to Cys528 of CRM1 (Figure 1b) [19]. The driving force of 
active nuclear transport appears to be the RanGTP (Ran = Ras-related nuclear protein) gradient between 
the nucleo- and the cytoplasm. CRM1 cooperatively binds RanGTP and the NES-containing cargo in the 
nucleus. Subsequent to transport through the NPC, RanGTP is hydrolyzed in the cytoplasm into RanGDP 
by the Ran GTPase-Activating Protein 1 (RanGAP), thereby triggering conformational changes 
resulting in cargo release. RanGDP is reimported into the nucleus by the Nuclear Transport Factor 2 
(NTF2) and converted into RanGTP by the nuclear Ran Guanine Nucleotide Exchange Factor 
(RanGEF/RCC1 - regulator of chromosome condensation 1). Importins depend on RanGTP to release 
their cargo in the nucleus and to be retransported into the cytoplasm by the export receptor Cellular 
Apoptosis Susceptibility (CAS) (for details see [14,18]). 
Nuclear transport in general is regulated by versatile signals such as hormones, cytokines, growth 
factors, cell cycle signals, developmental signals or stress. Hence, regulated nucleo-cytoplasmic 
transport is accepted as an efficient way to control the activity of a variety of proteins involved in 
physiological and pathophysiological processes [20,21]. As such, NLSs as well as leucine-rich NESs 
have been identified in an increasing number of disease relevant cellular and viral proteins implicated 
in transcription control, cell cycle control, mitosis and RNA transport (see [10,22-24]). 
Regulation can either occur through the expression status of transport components and/or at the 
level of the transported cargo itself. Dynamic exposure of transport signals due to conformational 
changes triggered by transient post-translational protein modifications, such as phosphorylation or Sensors 2009, 9                  
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acetylation, are known to modulate transport and the biological activities of proteins ([25] and 
references within). Interestingly, even isolated NESs can be grouped into specific kinetic classes 
according to their activity in vivo (Figure 1c), which appear to correlate with the biological activity of 
the proteins the NESs are originating from [23,26]. 
As regulated subcellular localization provides also an attractive way to rationally control the 
activity and stability of regulatory proteins and RNAs, targeting nucleo-cytoplasmic transport as a 
novel therapeutic principle has attracted major interest by academia and industry (see [20,23]). 
However, despite intense investigation the detailed molecular mechanism regulating the complex 
orchestration of nucleo-cytoplasmic transport is still not understood. Thus, in addition to genetic 
depletion strategies and sophisticated in vitro models employing the recent advances of 
nanotechnology [12,15], novel approaches such as chemogenomic screens will most likely aid in 
dissecting regulatory mechanism and contribute to clarifying cargo specificity. 
 
1.3. Chemogenomics 
 
Chemogenomics is the study of the interaction of biological systems with exogenous small 
molecules, i.e., analyzing the intersection of biological and chemical spaces (see [27,28]). Biological 
entities can be isolated proteins or more complex systems, such as living cells, which can be analyzed 
at the genomic, transcriptomic, proteomic or phenotypic level. The chemical space of small molecules 
consists of the current commercial and academic collections of compounds, and the virtual space, 
represented by all compounds possibly synthesizable. A major challenge of cheminformatics is 
therefore to charter the virtual space of small molecules using realistic biological constraints 
(bioavailability, druggability, structural biological information). Small molecules that allow a chemical 
knock out of a cellular reaction or a cell phenotype can be selected by phenotypic screens, and used as 
molecular tools to identify previously uncharacterized proteins and/or molecular mechanisms 
responsible for the given phenotype. This experimental approach termed forward chemogenomics 
(“from small molecules to targets”) defines chemogenomics at the intersection of the biological space 
with that of “small molecules”, rather than with the space of “drugs” that must comply with the 
restrictive approval conditions for therapeutics [27]. Consequently, we here describe and employ 
translocation biosensors as cellular system integrators to dissect nuclear export by chemogenomics. 
 
2. Results and Discussion 
 
2.1. The RevNES-Biosensor 
 
The applications of translocation biosensors for high-throughput cell based assays critically depend 
on robust and reliable biological readout systems with a high signal to noise ratio. Previously, we 
showed that the intracellular localization of a GST-GFP fusion strictly depends on the presence of 
transport signals and is not disrupted by passive diffusion [29]. In addition, GST-GFP is highly 
fluorescent, non-toxic and stable. To design a GFP-GST shuttle protein with a predominantly 
cytoplasmic steady-state localization, an appropriate combination of NLS and NES had to be used. 
Based on our kinetic classification studies (Figure 1c) [26], we combined the SV40 large T-antigen Sensors 2009, 9                  
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NLS (NLS) and the NES from the HIV-1 Rev protein (RevNES), to generate plasmids allowing the 
ectopic expression of a NLS-GFP/GST-RevNES fusion protein (RevNES-biosensor) (Figure 2a). 
Transient expression in several cancer cell lines confirmed that the RevNES-biosensor localized 
predominantly in the cytoplasm, was efficiently shuttling between the nucleus and the cytoplasm, and 
accumulated in the nucleus upon treatment with the CRM1 inhibitor LMB (Figure 2 b/c, and data not 
shown).  
Hence, the system appeared to be applicable for high-throughput redistribution screening 
applications. For this purpose, the nucleus of interphase cells was defined as the “CIRCN” region by 
staining with the nucleic acid dye Hoechst 33342 (channel 1). In the GFP-channel (channel 2), the 
CIRCN mask was eroded to reduce cytoplasmic contamination within the nuclear area, and the reduced 
mask (CIRC) was used to quantify the amount of GFP fluorescence before and after export inhibition 
within the nucleus (Figure 2c). Subsequently, the nuclear mask was dilated to cover as much of the 
cytoplasmic region as possible without going outside the cell boundary. Removal of the CIRC region 
from this dilated mask creates the RING mask covering the cytoplasmic region outside the nuclear 
envelope (Figure 2c). 
Figure 2. (a) Schematic representation of the modular RevNES-biosensor. (b) In living 
HeLa cells transiently expressing the RevNES-biosensor, the protein localized 
predominantly to the cytoplasm, whereas treatment with LMB resulted in its nuclear 
accumulation. Scale bar, 10 μm. (c) Schematic illustration of the masks used to mark the 
nucleus and the cytoplasm in order to define the cytoplasmic to nuclear translocation of the 
autofluorescent biosensor (details see text). 
 
 
2.2. Generation and Characterization of Cell Lines Stably Expressing the RevNES-Biosensor 
 
For high-throughput cellular assays it is time consuming and costly to continuously generate cells 
transiently expressing the biosensor by transfection. Thus, we engineered cells stably expressing the 
RevNES-biosensor by retroviral transduction of the epithelial carcinoma cell line A431. Subsequently, 
a highly fluorescent cell population was established by G418-selection and enriched by two rounds of 
fluorescence activated cell sorting (FACS, Figure 3a/b). The stable expression as well as the efficient 
cytoplasmic to nuclear redistribution of the biosensor was controlled in the resulting A431bio cell line 
by fluorescence microscopy prior and subsequent to LMB treatment (Figure 3c). Upon cultivation in 
selection media, expression of the biosensor was stable for at least four months (data not shown). Sensors 2009, 9                  
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Figure 3. Generation and characterization of RevNES-biosensor expressing cell lines.   
(a/b) A431 were transduced with pINCO_Rev-sensor containing retroviruses and subjected 
to two rounds of FACS sorting. A distinct cell population based on cell size (gate R1, left 
panels) and GFP fluorescence intensity (gate R2, right panel), was isolated. For the second 
round of FACS, only cells robustly expressing the RevNES biosensor were selected (b, R2 
right panel). (c) Fluorescent microscopic images of the A431bio cell population isolated 
after two rounds of FACS. All cells showed a high expression of the RevNES-biosensor, 
which localized predominantly in the cytoplasm with some accumulation at the nuclear 
membrane (left panel). Treatment with LMB (10 nM; 2h) resulted in almost complete 
accumulation of the biosensor in living cells. Scale bar, 10 μm. 
 
 
2.3. Assay Development on the Cellomics ArrayScan® VTI Imaging Platform 
 
To perform HTS the assay had to be adapted to the 384-well plate format. For this purpose, the 
molecular translocation assay was adjusted by modifying several parameters to ensure an optimal 
object identification (Figure 4a). The first step was to adjust the background correction and to define 
the threshold of pixels derived from the Hoechst 33342 signal. This calculation resulted in an 
optimized object identification, capable to automatically excluding “non cellular” irregular objects (too 
small/big, debris, compound aggregates, etc.) in channel 1. By adjusting object segmentation 
parameters, the fitting of the nuclear mask to the Hoechst 33342 signal was further optimized. Also for 
channel 2, the background correction and values for the threshold of the GFP signal were defined to 
exclude irregular and potentially false positive signals from the analysis. The translocation index is 
calculated as the difference of the nuclear intensity minus the cytoplasmic ring intensity (CIRC-RING) 
on a single cell basis. Of note, these parameters might have to be further adapted to the morphology of 
the cell type used for screening. 
In order to select an appropriate time point for assay execution, we next examined the kinetics of 
export inhibition caused by LMB, a drug that efficiently prevents the CRM1/NES-interaction by 
covalently binding to Cys528 of CRM1 (Figure 1b) [19]. As shown in Figure 4b, LMB treatment of 
A431bio cells caused rapid export inhibition resulting in almost complete nuclear accumulation of the 
biosensor already after 30min. A similar kinetic of inhibition was observed when cells were seeded in Sensors 2009, 9                  
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384-well plates and analyzed using the Cellomics ArrayScan
® VTI imager (Figure 4c). Addition of 
LMB resulted in a ~five-fold increase of the translocation index (CIRC-RING) in a roughly linear 
fashion over time, which remained stable after two to at least five hours post treatment (Figure 4d, and 
not shown). LMB is known as a “fast acting” irreversible export inhibitor [30], which we found not to 
cause obvious cytotoxic effect even after a 5  h treatment period (Figure 4b). Of note, prolonged 
incubation with LMB was toxic for the cells as demonstrated by analyzing cell viability (Suppl. 
Figure 1a). Since our goal was to also identify export antagonists with slower and thus, potentially 
different biochemical modes of action, 5  h was selected as the standard incubation time for the 
screening of the compound library. 
To finally establish the optimal assay cell density, A431bio cells were seeded in 384-well plates at 
0.6, 0.8 and 1 × 10
4 cells per well. Cells were treated with 10nM LMB or the DMSO control (0.4% 
final concentration), and analyzed using the Cellomics ArrayScan
® VTI imager to quantify the 
translocation response at all three seeding densities (Figure 4e). Employing our optimized object 
selection and assay parameters (Figure 4a), the cell density established by seeding 1 × 10
4 cells 
resulted in an optimal translocation index and thus, was selected for screening. Of note, the low 
DMSO concentrations used (0.4% final concentration) did not induce any detectable cellular effects 
when compared to PBS (not shown). 
Table 1. Translocation screen summary and assay performance data. 
Compound parameters 
  N° compounds  % of total 
Screened 16,671  100% 
Rescreened 120  0.72% 
Validated 11  0.07% 
Screening parameters 
Parameter Value 
# plates  48 
Total scan time  56h 
Scan time/well  11s 
Fields/well 4 
Average valid objects/well  470 
Z' factor calculation 
Formula Z'  factor 
CIRCGFP   0.71 
RingGFP -0.22 
CIRCGFP/ RingGFP 0.37 
CIRCGFP - RingGFP 0.77 
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Figure 4. (a) Optimized object selection parameters (min/max settings) for channel 1 and 2 
(highlighted in blue and green, respectively). (b) LMB treatment (10 nM) of A431bio cells 
resulted in a rapid nuclear accumulation of the biosensor already after 30 min, which 
remained stable also after 5 h without obvious cytotoxic effect on cell morphology. Scale 
bar, 10  μm. (c) Translocation assay analysis of A431bio cells using the Cellomics 
Arrayscan
® VTI platform. The Hoechst and GFP signals were recorded in channel 1 and 2 
(highlighted in blue and green), respectively, following LMB treatment (10 nM, 5 h). In 
the upper panel, the original raw images are shown. The lower panel shows the overlay 
with the respective masks. In channel 1, cells selected for further analysis are outlined in 
blue, cells rejected due to their size or shape are outlined in orange. In channel 2, the CIRC 
mask and RING region are outlined in green or red, respectively. Scale bar, 50 μm. (d) 
Average signal difference (CIRC-RING) of LMB treated cells (10 nM, 5 h) versus DMSO 
assay controls in one representative 384-well plate. 1 × 10
4 cells/well were seeded, and the 
values were derived from analyzing ~500 cells/well (see Table 1 for details) revealing a 
translocation index of > 5-fold. (e) Differences in assay performance depending on cell 
density. The indicated numbers of A431bio cells were seeded into 384-well plates. Sixteen 
h later, cells were treated with LMB (10 nM) or DMSO as a control for 5 h, and the 
translocation index quantitated using the Cellomics Arrayscan
® VTI imager. CIRC-RING 
differences were plotted for DMSO control (grey) and LMB treated (red) cells (left scale). 
The ratio of these values (white columns) performed best for 1 × 10
4 seeded cells/well. 
Columns, mean; bars, SD. 
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2.4. Biosensor-Based HTS for Export Inhibitors 
 
Subsequent to the evaluation and optimization of the assay parameters, the A431bio cells were used 
to screen the 17K ChemBioNet compound collection in a 384-well plate format employing the 
Cellomics ArrayScan
® VTI platform. The ChemBioNet compound collection used for screening was 
selected according to the Lipinski rules (“Rule of five”) [31]. In the context of the ChemBioNet library, 
these rules were used to select molecules predicted of being able to pass through biological membranes, 
including the plasma as well as the nuclear membrane and thus, are suitable for cellular assays. Based 
on the assay signal window and Z’-factor data (Table 1), the active criterion for the primary screen 
was set at a compound translocation index > 2 (Ti = compound(CIRC-RING)/DMSO(CIRC-RING)). Each plate 
contained a row with DMSO treated control cells and a row with LMB treated cells allowing to define 
the dynamic assay range for the individual plates and to also monitor the robustness of the assay. Only 
valid objects, i.e., cells that pass the object selection criteria (Figure 3a) were included in the analysis. 
In the course of the screen, a total of 16,671 compounds were tested at a final concentration of 
25 μM (corresponding to a DMSO concentration of 0.4%) for their ability to inhibit export of the 
RevNES-biosensor. The complete HTS assay was performed in five days. The total scan time for the 
primary screen on the Cellomics ArrayScan
® VTI platform was 56 h, the mean scan time/well was 11 s, 
and the average number of valid objects (= cells) was 470 (Table 1). Although we used stringent 
parameters to optimize automated object identification and exclusion of “non cell objects” together 
with our translocation algorithm, the primary assay identified ~500 events as “potential hits”, causing 
a Ti > 2. 
To separate “true” from “false positive” hits, we made use of the ArrayScan
® view software. This 
option to reinspect the actual images from the plate controls, empty wells or the compound wells is a 
major advantage of the Cellomics ArrayScan
® VTI microscopy-based cellular screening assay, and a 
clear advantage compared to enzymatic in vitro assays [3]. Employing the ArrayScan
® view software, 
we found that among the “potential hits” were autofluorescent substances, cytotoxic compounds (for 
examples, see Figure 5), or substances that triggered intracellular aggregation of the biosensor (~380). 
As shown in Figure 5c (upper panel), autofluorescent substances can mimic a “true” translocation 
event. Likewise, cytotoxic compounds can induce apoptosis of the indicator cells, leading to loss of 
cell morphology, condensation of the nucleus and/or biosensor-aggregation (Figure 5c, lower panel). 
Cytotoxicity was primarily determined by visual inspection, and verified by analyzing cell viability for 
selected compounds (Suppl. Figure 1a, and data not shown). Such structures were passing the intensity 
and size filters selected in the algorithm. Hence, for future applications the development of additional, 
more stringent assay parameters is desirable, which should be used especially in secondary screen to 
automatically subclassify potential hit compounds. However, also compounds causing off-target 
effects may represent interesting and also biologically relevant chemical tools for forward 
chemogenomics (“from small molecules to targets”). Of note, the majority of drugs currently used as 
anti-cancer chemotherapeutics can be classified as “cytotoxic compounds”. Hence, it will be of general 
interest to dissect the molecular mechanisms by which these novel cytotoxic substances identified in 
our biosensor assay execute their cell damaging effects by employing in silico modeling as well as in 
vitro  studies. From the ~500 “potential hits” identified by the primary screen, visual inspection 
resulted in the selection of 120 compounds (0.7%), which were neither autofluorescent nor cytotoxic at Sensors 2009, 9                  
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the tested concentration (25 μM) and induced efficient nuclear export inhibition (Ti > 2) in a secondary 
Cellomics Arrayscan
® VTI based-screen (Figure 6a). Eleven representative compounds were 
subsequently ordered for a detailed “in lab evaluation” by fluorescence microscopy. 
 
Figure 5. Intersection of the biological and chemical space. Translocation index-based 
analysis for cytotoxicity and fluorescence interference. (a) CIRC-RING values 
representative for negative and positive control substances (DMSO, LMB), export 
antagonists, substances showing no effect on export, cytotoxic and autofluorescent 
compounds obtained from the analysis of a representative 384-well plate. (b) Scatter plot of 
the nuclear intensity/well versus the cytoplasmic intensity/well in the “green” target 
channel 2 (GFP) subsequent to compound exposure to mark the intersection of the 
chemical and biological space. Values from a representative 384-well plate are shown. The 
DMSO controls (dark grey) are grouped together with the non-hit compounds (light grey), 
and are well separated from the LMB controls (red) and a potential hit population (black 
dotted circle). Potential hit compounds partially overlap with cytotoxic substances (violet), 
identified by visual inspection. Autofluorescent compounds (orange) usually display high 
fluorescence intensities and are well separated. (c) Representative images from compound 
wells that exhibited either a dose-dependent autofluorescence (upper panel) or a dose-
dependent cytotoxicity (lower panel). Raw images and mask overlays are shown for both 
channels. In the Hoechst channel, objects selected for further analysis are outlined in blue, 
objects rejected are outlined in orange. In the “GFP channel”, the green outline represents 
the nuclear region mask, and the red outline the cytoplasmic ring region. Scale bar, 50 μm. 
The chemical structure of the respective compounds are shown on the right. 
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Figure 5. Cont. 
 
 
 
2.5. Functional and Kinetic Profiling of Novel Export Antagonists 
 
These eleven compounds showed inhibitory activity not only in A431bio cells on the ArrayScan
® 
platform (Figure 6a), but also caused nuclear accumulation of the RevNES-biosensor when tested in 
several epithelial cancer cell lines (Suppl. Figure 1b). So far, we did not observe a cell line-specific 
difference in their activity. Importantly, when we analyzed the kinetics of inhibition, we found that the 
export antagonists could be classified into fast or slow acting compounds with an irreversible or 
reversible mode of inhibition (Figure 6c/d). As depicted, compound C3 blocked export as fast as LMB, 
but the inhibition was completely reversed after 24 h (Figure 6c/d). Such a bioactivity profile suggests 
that C3 inactivates CRM1 not by covalent binding to the active NES-interacting pocket as shown for 
LMB [19], and appears to be unstable under physiological conditions. In contrast, C5 is a slow acting 
compound, which irreversibly inhibits nuclear export. Such a delay in export inhibition might be 
explained by the reduced ability of the substance to enter the cell and/or the nucleus. However, the 
exact molecular mechanisms and protein targets of the identified inhibitors remain to be resolved by 
employing comprehensive experimental approaches. 
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Figure 6. (a) Secondary ArrayScan
®-based validation of potential export antagonists. 
1 × 10
4 A431bio cells/well were seeded into 384-well plates. 16 h later, cells were treated 
with LMB (10nM), DMSO or the indicated compounds (C1-C11; 25 µM) for 5 h, and 
translocation was quantitated using the Cellomics ArrayScan
® VTI imager. The CIRC-
RING differences are indicative of efficient export inhibition. Columns, mean; bars, SD.  
(b) In lab verification of hit compound performance in living HeLa cells transiently 
expressing the RevNES biosensor. Indicated compounds were applied at a concentration of 
25 µM for 5 h, resulting in efficient nuclear accumulation of the biosensor. Scale bar, 10 
μm. (c) Compound specific kinetics of inhibition. HeLa cells transiently expressing the 
RevNES biosensor were treated with LMB (10nM) or the indicated compounds (25 µM). 
The localization of the biosensor is shown at the indicated time points when the 
compounds displayed their maximum inhibitory activity (top panel), as well as 24 h post 
treatment. The inhibitory activity of C3 and C11 was reversed after 24 h. Scale bar, 10 μm. 
(d) Kinetic activity profile of export inhibitors. Selection of different time points (indicated 
by the arrows) for snapshot analysis (highlighted in grey) may significantly influence the 
number and type of compounds identified in primary screens. A continuous kinetic 
monitoring of the biosensor translocation may ensure the identification of the maximum 
number of bioactive substances and the optimal extraction of informations concerning their 
bioactivity. Time point used for analysis of the primary RevNES-biosensor screen is 
marked by the asterisks. An optimal kinetic window is highlighted in blue.  
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Figure 6. Cont. 
 
Besides the identification of novel transport inhibitors, our approach also impressively underlines 
the enormous advantage of kinetic biosensors compared to snapshot assays. Our biosensor assay 
allows to continuously monitoring the translocation process in living cells in order to identify the 
maximum number of potentially bioactive substances and to simultaneously extract important 
information concerning the cellular bioactivity and pharmacology of the compounds. The kinetic 
activity profile illustrated in Figure 6d demonstrates that the discovery rate and type of molecules can 
be rationally influenced by the kinetic window selected for assay analysis. Within drug discovery 
projects, this may result in a significant enrichment for hits with a desired mode of activity, e.g., fast 
acting inhibitors, and thus, significantly reduces the number of compounds, which have to be validated 
and biologically characterized by time consuming and costly assays downstream in the drug 
development pipeline. 
 
3. Experimental Section 
 
3.1. Plasmids 
 
To construct the retroviral expression vector, pINCO_Rev-sensor, the coding region for BFP in the 
PINCO vector [32] was replaced by the NLS-GFP/GST-RevNES (RevNES-biosensor) expression 
cassette [3] by cloning into the BamHI/NotI-restriction sites. The plasmid was verified by sequence 
analysis according to [3]. 
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3.2. Cell Culture, Transfection, Retrovirus Production and Transduction 
 
A431 and HeLa cell lines were maintained under conditions described [33] and transfected with 
plasmid DNA using Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) according to [34]. 
Production of retroviral stocks and transduction were carried out as previously described [33]. 
 
3.3. Generation of Stable Cell Lines 
 
To generate cells stably expressing autofluorescent RevNES-biosensor protein, A431 cells were 
transduced with pINCO_Rev-sensor. Subsequently, cells were cultured in the presence of 500 µg/mL 
G418 (Sigma Aldrich, Munich, Germany). A highly fluorescent cell population (A431bio) was isolated 
by fluorescence activated cell sorting (FACS), which was repeated after two weeks cultivation of the 
cells in G418-containing selection media as described [33]. 
 
3.4. Automated High Throughput/Content Screening Platform, Assay Preparation and Execution 
 
Automated assay analysis was performed using the Cellomics ArrayScan
® VTI Imaging Platform 
(Thermo Fisher Scientific Inc., Berkshire, UK), an automated fluorescence microscopic imaging 
system. Biosensor expressing A431bio cells were detached with trypsin (Invitrogen, Karlsruhe, 
Germany) and counted in a Fuchs-Rosenthal chamber (Roth, Karlsruhe, Germany) as described [3]. 
Cells were seeded with an electronic multichannel pipette (Eppendorf, Hamburg, Germany) into 384-
well thin bottom Greiner µclear
® plates (Greiner, Frickenhausen, Germany) in a final volume of 50 µL 
cell culture medium per well. Prior to seeding, the plates were coated with poly-L-lysine (Sigma 
Aldrich, Munich, Germany). The compounds of the ChemBioNet library were added with a liquid 
handling robot (Sciclone ALH-3000, Caliper Life Sciences, Rüsselsheim, Germany) at a final 
concentration of 25 µM. Plates were incubated at 37 °C, 5% CO2 and 95% humidity. On each plate, 
DMSO (0.4%) was added to one row as a negative control and LMB (10nM) to another row as a 
positive control. After 5 h of incubation with the compounds, cells were fixed by the addition of 50 µL 
4% PFA (Sigma Aldrich, Munich, Germany) for 20 min. Subsequently, plates were washed three times 
with PBS using an ELISA washer (ELX405UV, BioTek, Bad Friedrichshall, Germany). Nuclei were 
stained by addition of Hoechst 33342 (Sigma Aldrich, Munich, Germany) at a final concentration of 
40 µM for 10 min. After a final wash with PBS, 50 µL PBS were left in each well and the plates were 
sealed and stored at 4 °C until analysis. 
 
3.5. Image Acquisition and Analysis  
 
Images were acquired and analyzed on the Cellomics ArrayScan
® VTI Imaging Platform. 
Fluorescence images were captured as described [3]. Briefly, Hoechst 33342 (excitation 405 nm, 
emission 400–450 nm) and GFP (excitation 470 nm, emission 509 nm) fluorescence [35] were 
captured using sequential acquisition to give separate image files for each. Binary image masks were 
created of GFP and Hoechst 33342 positive staining to define regions of interest (ROI) for analysis. 
This was done by applying a median filter (3 × 3 pixel radius) to remove noise and to approximate the Sensors 2009, 9                  
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distribution of staining intensity to a median value. Automatic thresholding using the Isodata 
algorithm [36] was used to convert the image to a binary mask that included all fluorescence data 
above background. The Hoechst 33342 staining (channel 1) mask was used to define the nuclear ROI. 
Subsequently, the Hoechst 33342 mask was subtracted from the GFP mask (channel 2) to create a 
staining mask defining the cytoplasmic ROI. Scans were performed sequentially with settings to give 
sub-saturating fluorescence intensity, and a minimum of 100 valid objects per well was recorded. 
 
3.6. The ChemBioNet Compound Collection 
 
The  ChemBioNet compound collection used for screening consists of a collection of 16,671 
compounds, selected according to the Lipinski rules (“Rule of five”) [31]. For the ChemBioNet library, 
these rules were used to select molecules, which are capable of passing through biological membranes 
and thus, are suitable for cellular assays. The average molecular weight of a compound in the 
screening collection is 388 g/mol and 80% of all compounds have a molecular weight between 300 and 
500  g/mol. There is no compound with more than five hydrogen bond donors and none of the 
compounds contains more than ten hydrogen bond acceptors. In addition, 90% of the compounds 
contain ten or fewer rotatable bonds. The screening library fulfils all criteria that are usually applied to 
select small molecules with a high bioavailability.  
 
3.7. Drug Treatment and Fluorescent Imaging of Cells 
 
Cells were treated with leptomycin B (LMB) (Sigma Aldrich, Munich, Germany) as described [37]. 
Compounds were purchased from ChemDiv (San Diego, CA, USA) and dissolved in DMSO (50 mM). 
Cell nuclei were marked by staining with Hoechst 33258 (Sigma Aldrich, Munich, Germany) as 
described [38]. Cells were observed as described [38], and twelve-bit black and white images captured 
using a digital AxioCam CCD camera (Carl Zeiss, Jena, Germany). Quantitation, image analysis and 
presentation were performed using the AxioVision
® software (Carl Zeiss, Jena, Germany). The total 
cellular GFP signal was measured by calculating the integrated pixel intensity in the imaged cell 
multiplied by the total area of the cell. The nuclear signal was similarly obtained by measuring the 
pixel intensity in the nucleus. The cytoplasmic signal was calculated by subtracting the nuclear signal 
from the total cellular signal. All pixel values were measured below the saturation limits, and the 
background signal in an area without cells was subtracted from all values. For in lab verification, at 
least 200 fluorescent cells from three separate images were examined to determine the average 
intracellular protein localization. 
 
3.8. Measurement of Cell Viability 
 
Cell viability was determined using the electric sensing zone method (CASY
® TT Cell Counter; 
Schärfe SystemGmbH, Reutlingen, Germany) and the CellTiter-Glo
® Luminescent Cell Viability 
Assay (Promega, Madison, WI) as described [39]. 
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3.9. Statistical Analysis 
 
Unless stated otherwise, the mean values and the standard deviations (SD) presented in the 
corresponding graphs are obtained from two independent experiments done in triplicate. For in lab 
verification, a minimum of 200 fluorescent cells from at least three separate images were examined to 
determine the average circ-ring GFP intensity difference as a measure for subcellular localization of 
the biosensor. 
 
4. Conclusions 
 
To date the detailed molecular mechanisms regulating the orchestration of nucleo-cytoplasmic 
transport are still not completely understood. Thus, in addition to biochemical studies systematic cell-
based screens need to be applied to unravel novel biochemical regulations and to hopefully also clarify 
cargo specificity. 
Here, we describe the establishment of a translocation-based cellular assay for HTS identification of 
general/specific export inhibitors, employing the Cellomics ArrayScan
® VTI imager. In order to avoid 
the contamination of "hit compounds" by substances, which indirectly interfere with transport, only the 
isolated NES sequence of the HIV-1 Rev protein was integrated as a model in the biosensor. Indirect 
transport inhibitors acting by the induction of intramolecular conformational changes in the NES-
containing cargo, e.g., by blocking phosphorylation have been already identified in several screens 
(see [20]). In contrast, the hit compounds discovered by our strategy appear not to influence potential 
modifications of the biosensor protein. Importantly, the identified compounds displayed different 
bioactivity profiles, allowing their classification into fast or slow acting substances with an irreversible 
or reversible mode of inhibition. 
Assuming that the compounds are not interacting with structural and/or functional components of 
the NPC (Figure 1a), several modes of action can be envisaged (Figure 7). First, similar to known 
export inhibitors such as LMB or N-azolylacrylates [40], the compounds may reversibly or irreversibly 
occupy the NES-binding pocket in CRM1, e.g., by covalently binding to critical amino acids residues, 
such as Cys528 [19]. Hence, CRM1 will be unable to accept the NES-containing cargoes for the 
assembly of a functional export complex with RanGTP. Second, the compounds may interact with 
CRM1 outside of the NES-binding domain thereby inducing conformational changes precluding the 
assembly of a functional export complex. In order to achieve a cargo specific nuclear export inhibition, 
the compounds need to target putative cofactors required for the assembly of protein specific export 
complexes. Alternatively, and more likely the compounds may directly interact with the nuclear export 
signal sequence, thereby blocking the binding of the NES-containing cargo to the CRM1/RanGTP 
complex. Since NESs can be grouped into specific categories according to their activity in vivo 
(Figure  1c), these differences may represent an attractive opportunity to selectively interfere with 
export and the biological functions of proteins by the identification of such NES-specific 
inhibitors  [26]. Currently, we are in the process of discriminating between these possibilities by 
investigating the inhibitory effects of the compounds on different shuttle proteins. Besides functional 
and biochemical assays, we are employing a set of translocation biosensors containing the NESes of 
proteins with high disease relevance in ArrayScan
®-based primary screens (see [3,25,37]. Sensors 2009, 9                  
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Figure 7. Model summarizing potential modes of action of the identified export inhibitors. 
Compounds may bind to CRM1 and, in an allosterical or competitive manner, affect its 
NES-binding domain, thereby preventing the assembly of a functional export complex. 
Alternatively, the compounds may directly interact with the specific NES itself or target 
putative cofactors required for the assembly of protein specific export complexes. 
Compounds displaying such a bioactivity profile would be of therapeutic interest. 
 
 
Although “LMB-like” inhibitors that irreversibly bind and inactivate CRM1 will most likely not be 
used in therapeutic applications, they have been and will be used in the future as valuable 
chemogenomic tools to dissect the regulation and (patho)physiological relevance of nucleo-
cytoplasmic transport. Moreover, compounds that are only transiently inactivating CRM1 and thus, 
may allow to interfere with nuclear export of regulatory proteins in a defined time window may have 
therapeutic potential, especially when combined with other targeted therapeutics, such as kinase 
inhibitors. Certainly, compounds that display a protein- or at least a protein class-specific inhibitory 
activity will most likely represent promising lead structures for the development of novel therapeutics 
for various diseases including cancer.  
In summary, the kinetic biosensor assay presented allowed the high-throughput identification of 
novel inhibitors from the ChemBioNet  compound collection, targeting the CRM1 nuclear export 
pathway. Our approach also represents a successful example for forward chemogenomics [27,28], 
which in combination with the recent technological and experimental developments in the area of 
reverse chemogenomics [41] will help to explore the intersection of the biological and chemical space. 
The detailed knowledge of the compounds' molecular mode of action will not only allow to identify 
chemical hit-to-lead scaffolds for future developments but will also aid in the building of a Chem-Bio 
data base to achieve an improved understanding of the chemical structure-biological function 
relationship. Sensors 2009, 9                  
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Supplementary Figure 1. (a) Prolonged incubation with LMB affects cell viability. 1x10
3 
A431bio cells/well were seeded into 96-well plates and treated with the indicated 
concentrations of LMB or were mock treated (DMSO). ATP concentrations in cell lysates, 
reflecting cell viability, were determined after the indicated time points using the CellTiter-
Glo
® Luminescent Cell Viability Assay (Promega, Madison, WI) as described [39]. 
Whereas LMB treatment for up to 5h did not show a significant effect, incubation for 24h 
resulted in a strong reduction in cell viability. No significant dose dependence was 
observed. RLU, relative light units; columns, mean; bars, SD. (b) The novel export 
inhibitors are active in cell culture models of different tumor types. Indicated cell lines 
transiently expressing the RevNES biosensor were treated with the indicated compounds 
(25 µM). The localization of the biosensor is visualized in living cells by fluorescence 
microscopy 5 h after mock (DMSO), 2 h after LMB treatment and at time points when the 
compounds displayed their maximum inhibitory activity (Topt). All export inhibitors 
blocked export in FaDu (head and neck cancer cell line), MDA-MB-231 (breast cancer cell 
line) or RKO (colon cancer cell line) cells. Scale bar, 10 μm.  
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